These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group. Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D; Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400 [TBL] [Abstract][Full Text] [Related]
28. High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma. Akhtar S; El Weshi A; Rahal M; Abdelsalam M; Al Husseini H; Maghfoor I Bone Marrow Transplant; 2010 Mar; 45(3):476-82. PubMed ID: 19734949 [TBL] [Abstract][Full Text] [Related]
29. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B. Nademanee A; Forman SJ Semin Hematol; 2006 Oct; 43(4):240-50. PubMed ID: 17027658 [TBL] [Abstract][Full Text] [Related]
30. Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French registry. Moreau P; Fleury J; Brice P; Colombat P; Bouabdallah R; Lioure B; Voillat L; Casasnovas O; François S; Sadoun A; Lamy T; Lotz JP; Munck JN; Divine M; Fermé C; Pény AM; Fruchart C; Oriol P; Ojeda M; Reman O; Milpied N; Gisselbrecht C; Legros M; Harousseau JL Bone Marrow Transplant; 1998 Apr; 21(8):787-93. PubMed ID: 9603402 [TBL] [Abstract][Full Text] [Related]
31. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease. Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918 [TBL] [Abstract][Full Text] [Related]
32. Autologous stem cell transplantation for advanced Hodgkin's disease in children. Spanish group for BMT in children (GETMON), Spain. Verdeguer A; Pardo N; Madero L; Martinez A; Bureo E; Fernández JM; Muñoz A; Olivé T; Fernández-Delgado R; Cubells J; Diaz MA; Sastre A Bone Marrow Transplant; 2000 Jan; 25(1):31-4. PubMed ID: 10654011 [TBL] [Abstract][Full Text] [Related]
33. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation. Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639 [TBL] [Abstract][Full Text] [Related]
34. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer]. Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945 [TBL] [Abstract][Full Text] [Related]
35. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557 [TBL] [Abstract][Full Text] [Related]
36. Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience. Ballova V; Ladicka M; Vranovsky A; Lakota J Neoplasma; 2008; 55(5):428-36. PubMed ID: 18665754 [TBL] [Abstract][Full Text] [Related]
37. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group. Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723 [TBL] [Abstract][Full Text] [Related]
38. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
39. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. Sweetenham JW; Carella AM; Taghipour G; Cunningham D; Marcus R; Della Volpe A; Linch DC; Schmitz N; Goldstone AH J Clin Oncol; 1999 Oct; 17(10):3101-9. PubMed ID: 10506605 [TBL] [Abstract][Full Text] [Related]
40. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. Gerrie AS; Power MM; Shepherd JD; Savage KJ; Sehn LH; Connors JM Ann Oncol; 2014 Nov; 25(11):2218-2223. PubMed ID: 25149708 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]